Amneal Pharmaceuticals (NASDAQ:AMRX) Releases Quarterly Earnings Results, Beats Estimates By $0.11 EPS

Amneal Pharmaceuticals (NASDAQ:AMRX) announced its quarterly earnings results on Wednesday. The company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.11, Zacks reports. Amneal Pharmaceuticals had a net margin of 2.39% and a negative return on equity of 228.24%. Amneal Pharmaceuticals updated its FY 2026 guidance to 0.950-1.050 EPS and its Q1 2026 guidance to 0.270-0.270 EPS.

Amneal Pharmaceuticals Stock Up 4.5%

Shares of AMRX opened at $13.61 on Wednesday. The stock has a market capitalization of $4.28 billion, a P/E ratio of 58.02 and a beta of 1.32. Amneal Pharmaceuticals has a twelve month low of $7.02 and a twelve month high of $15.42. The company has a 50 day moving average of $13.17 and a 200-day moving average of $12.53.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Rubric Capital Management LP grew its position in Amneal Pharmaceuticals by 5.3% in the third quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company’s stock valued at $123,473,000 after purchasing an additional 624,609 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Amneal Pharmaceuticals by 3.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 5,609,040 shares of the company’s stock worth $70,681,000 after buying an additional 177,906 shares in the last quarter. Morgan Stanley lifted its position in Amneal Pharmaceuticals by 37.5% during the 4th quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock worth $60,708,000 after buying an additional 1,315,018 shares in the last quarter. Nantahala Capital Management LLC boosted its stake in shares of Amneal Pharmaceuticals by 14.7% during the 2nd quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company’s stock worth $35,333,000 after buying an additional 558,877 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Amneal Pharmaceuticals by 3.4% during the 4th quarter. State Street Corp now owns 4,110,410 shares of the company’s stock worth $51,791,000 after buying an additional 136,662 shares during the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Key Amneal Pharmaceuticals News

Here are the key news stories impacting Amneal Pharmaceuticals this week:

• Positive Sentiment: Q1 results and near-term guidance beat expectations: Amneal reported Q1 EPS of $0.26 vs. the $0.15 consensus and provided Q1 EPS guidance of $0.270 (above the $0.160 consensus) and revenue guidance of $723M vs. $715M consensus — evidence of stronger-than-expected core performance. AMRX Marketbeat earnings summary
• Positive Sentiment: Raised FY2026 outlook: Amneal set FY2026 EPS guidance of $0.95–1.05 (vs. $0.95 consensus) and revenue guidance of $3.1B–$3.2B, signaling management expects continued top-line growth for the year. GlobeNewswire release on acquisition and guidance
• Positive Sentiment: Acquisition to build biosimilars scale: Amneal agreed to acquire Kashiv BioSciences for up to $1.1B (cash + stock) to expand biologics development and manufacturing capabilities and target a large loss-of-exclusivity market — a strategic move to diversify into higher-margin complex therapies. The deal requires shareholder and regulatory approvals and is expected to close in H2 2026. Reuters: Amneal to buy Kashiv BioSciences
• Neutral Sentiment: Positive clinical news for Crexont supports product growth thesis: Interim Phase 4 ELEVATE‑PD data show meaningful increases in “good on” time for Crexont in Parkinson’s patients, supporting commercial upside for key specialty products. Business Insider: Crexont Phase 4 results
• Negative Sentiment: Profitability and capital structure remain concerns: despite the beat, Amneal’s reported net margin is low (~2.4%) and return on equity is deeply negative (−228%), highlighting ongoing profitability and balance-sheet issues that could amplify market sensitivity to the Kashiv deal and any financing/dilution. AMRX Marketbeat financials

Analysts Set New Price Targets

AMRX has been the topic of a number of research analyst reports. UBS Group began coverage on shares of Amneal Pharmaceuticals in a report on Friday. They set a “buy” rating and a $19.00 price objective on the stock. Truist Financial increased their target price on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Weiss Ratings reissued a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 21st. Finally, Zacks Research lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $15.00.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.